CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $321,000 | +221.0% | 10,804 | +93.1% | 0.00% | – |
Q2 2023 | $100,000 | +85.2% | 5,595 | +64.8% | 0.00% | – |
Q1 2023 | $54,000 | -57.1% | 3,394 | -50.7% | 0.00% | – |
Q4 2022 | $126,000 | +530.0% | 6,890 | +584.2% | 0.00% | – |
Q3 2022 | $20,000 | +53.8% | 1,007 | +52.1% | 0.00% | – |
Q2 2022 | $13,000 | -80.9% | 662 | -78.6% | 0.00% | – |
Q1 2022 | $68,000 | -75.6% | 3,088 | -68.6% | 0.00% | – |
Q4 2021 | $279,000 | +304.3% | 9,823 | +199.8% | 0.00% | – |
Q3 2021 | $69,000 | +25.5% | 3,277 | +13.1% | 0.00% | – |
Q2 2021 | $55,000 | +103.7% | 2,897 | +62.2% | 0.00% | – |
Q1 2021 | $27,000 | +237.5% | 1,786 | +215.0% | 0.00% | – |
Q4 2020 | $8,000 | +700.0% | 567 | +1432.4% | 0.00% | – |
Q3 2020 | $1,000 | -91.7% | 37 | -94.9% | 0.00% | – |
Q2 2020 | $12,000 | +200.0% | 723 | +162.0% | 0.00% | – |
Q1 2020 | $4,000 | -66.7% | 276 | -42.7% | 0.00% | – |
Q4 2019 | $12,000 | +100.0% | 482 | +16.1% | 0.00% | – |
Q3 2019 | $6,000 | -40.0% | 415 | 0.0% | 0.00% | – |
Q2 2019 | $10,000 | +11.1% | 415 | 0.0% | 0.00% | – |
Q1 2019 | $9,000 | +800.0% | 415 | +1283.3% | 0.00% | – |
Q4 2018 | $1,000 | -88.9% | 30 | -90.9% | 0.00% | – |
Q3 2018 | $9,000 | – | 328 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |